Malaria Patents (Class 514/895)
  • Patent number: 7851512
    Abstract: The present invention provides a novel combination comprising artemisinin in the form of tablets and related dosage forms for pediatric use, such as granules, suppository, suspension syrup and dry powder, for the treatment of human malarias including multiple-resistant subtertian malaria, tertian malaria and quartan malaria. The combination is comprised of artemisinin, piperaquine and primaquine. Clinical tests in Southeast Asia countries where malaria is epidemic demonstrate that, apart from having high and rapid therapeutic effect possessed by the most excellent domestic and foreign artemisinin-type anti-malarial drugs, the present combination is also featured with shorter course of treatment, less side effect, lower material cost, and more convenience for administration, and its ability of rapidly killing gametophyte and cutting off infection source thereby blocking spreading of malaria is a further improvement.
    Type: Grant
    Filed: September 20, 2004
    Date of Patent: December 14, 2010
    Inventors: Li Guogiao, Jianping Song
  • Patent number: 7629365
    Abstract: 3-Chloro-6-(hydroxymethyl)-2-methyl-5-[4-({4-[(trifluoromethyl)oxy]phenyl}oxy)phenyl]-4(1H)-pyridinone, having the following formula: is described along with its pharmaceutically acceptable salts, processes for its preparation, pharmaceutical formulations thereof and its uses in treatment of certain parasitic infections such as malaria.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: December 8, 2009
    Assignee: Glaxo Group Limited
    Inventors: Jose Maria Bueno Calderon, Jesus Chicharro Gonzalo, M Pilar Manzano Chinchon
  • Patent number: 7157449
    Abstract: The present invention relates to the use of an inhibitor of CTP synthetase, such as a glutamine analogue, and a substance capable of suppressing toxic effects thereof in vivo, in the manufacture of a medicament for the treatment of a disease caused by a parasitic protozoa. More specifically, said substance capable of suppressing toxic effects may be a nucleobase, such as a purine base or a nucleoside, while the glutamine analogue advantageously is 6-diazo-5-oxo-L-norleucine (DON). The invention also relates to a pharmaceutical composition as such for the treatment and/or prevention of a disease caused by a parasitic protozoa, wherein the disease is selected from the group consisting of malaria, leishmaniasis and trypanosomiasis, e.g. American trypanosomiasis (Chaga's disease), or African trypanosomiasis (African sleeping sickness).
    Type: Grant
    Filed: April 20, 2001
    Date of Patent: January 2, 2007
    Inventors: Anders Hofer, Lars Thelander
  • Patent number: 7135195
    Abstract: We disclose a colorless composition comprising silver particles and water, wherein said particles comprise an interior of elemental silver and an exterior of ionic silver oxide, wherein the silver particles are present in the water at a level of about 5–40 ppm, and wherein the composition manifests significant antimicrobial properties. Methods of use of the composition are described.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: November 14, 2006
    Assignee: American Silver, LLC
    Inventors: Robert J. Holladay, Herbert Christensen, William D. Moeller
  • Patent number: 7084132
    Abstract: A stable form of artemisinin wherein an artelinic acid or artesunic acid is complexed with cyclodextrin analogs, preferably, ?-cyclodextrin. The complexed cyclodextrin artemisinin formulation shields the peroxide portion of the artemisinin backbone from hydrolytic decomposition rendering it stable in solution. Artelinic acid and cyclodextrin are placed into contact with one another to yield a 2:1 molecular species. Artesunic acid and cyclodextrin yield a 1:1 molecular species. The complexed cyclodextrin artemisinin formulation is effective for the treatment of malaria and is stable in solution for long periods of time.
    Type: Grant
    Filed: April 25, 2005
    Date of Patent: August 1, 2006
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Mark G. Hartell, Apurba K. Bhattacharjee, Rickey P. Hicks, John E. VanHamont, Wilbur K. Milhous
  • Patent number: 6951846
    Abstract: A stable form of artemisinin wherein an artelinic acid or artesunic acid is complexed with cyclodextrin analogs, preferably, ?-cyclodextrin. The complexed cyclodextrin artemisinin formulation shields the peroxide portion of the artemisinin backbone from hydrolytic decomposition rendering it stable in solution. Artelinic acid and cyclodextrin are placed into contact with one another to yield a 2:1 molecular species. Artesunic acid and cyclodextrin yield a 1:1 molecular species. The complexed cyclodextrin artemisinin formulation is effective for the treatment of malaria and is stable in solution for long periods of time.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: October 4, 2005
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Mark G. Hartell, Apurba K. Bhattacharjee, Rickey P. Hicks, John E. VanHamont, Wilbur K. Milhous
  • Patent number: 6664397
    Abstract: Use of (+)-(11R,2′S)-&agr;-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol or a pharmaceutically acceptable salt thereof substantially free of its (−)-enantiomer in the manufacture of a medicament having reduced side-effect compared to the racemic (±)-(R*,S*)-&agr;-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol for treating or preventing malaria in a subject. A method of treating or preventing malaria with reduced side-effects comprising administration of (+)-(11R,2′S)-&agr;-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol or a pharmaceutically acceptable salt thereof substantially free of its (−)-enantiomer.
    Type: Grant
    Filed: November 22, 1999
    Date of Patent: December 16, 2003
    Assignee: Vernalis Research Limited
    Inventors: Allan Fletcher, Robin Shepherd
  • Patent number: 6645966
    Abstract: Disclosed is a method of treating Malaria comprising administering an effective amount of an FPT inhibitor to a patient in need of such treatment alone or in combination with an additional antimalarial agent and/or agent for reversing antimalarial resistance. Also disclosed are novel Farnesyl Protein Transferase inhibitors.
    Type: Grant
    Filed: January 18, 2002
    Date of Patent: November 11, 2003
    Assignee: Schering Corporation
    Inventors: William T. Windsor, Patricia C. Weber, Corey O. Strickland, Michael Gelb
  • Patent number: 6531487
    Abstract: Compounds, compositions and methods are provided for treating malaria parasites in vitro and in vivo by administering indolo[2,1-b]quinazoline-6,12-dione compounds of Formula I.
    Type: Grant
    Filed: May 8, 2001
    Date of Patent: March 11, 2003
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Kevin K. Pitzer, John P. Scovill, Dennis E. Kyle, Lucia Gerena
  • Patent number: 6528519
    Abstract: The specification discloses the treatment of malaria through the use of tetrandrine and its derivatives.
    Type: Grant
    Filed: February 28, 1991
    Date of Patent: March 4, 2003
    Inventor: Knox Van Dyke
  • Patent number: 6428983
    Abstract: Histone deacetylase inhibition provides a target for identifying potential antiprotozoal compounds. Histone deacetylase inhibitors are useful as therapeutic agents against protozoal infections.
    Type: Grant
    Filed: April 22, 1999
    Date of Patent: August 6, 2002
    Assignee: Merck & Co.
    Inventors: Paula M. Dulski, Robert W. Myers, Anne M. Gumett, Sandra J. Rattray, Dennis M. Schmatz
  • Patent number: 6376688
    Abstract: The present invention provides polyunsaturated fatty acid compounds having antimalarial and/or neutrophil stimulatory activity. The polyunsaturated fatty acids contain 18-25 carbons and 1-6 double bonds and are characterized in that they have one or two substitutions selected from the group consisting of &bgr; oxa, &ggr; oxa, &bgr; thia and &ggr; thia. It is also preferred that the polyunsaturated fatty acid compound includes a further substitution selected from the group consisting of hydroxy, hydroperoxy, peroxy, carboxymethyl substitutions or attached to an amino acid.
    Type: Grant
    Filed: May 29, 1997
    Date of Patent: April 23, 2002
    Assignee: Peptide Technology Limited
    Inventors: Antonio Ferrante, Alfred Poulos, Christopher John Easton, Michael Joseph Pitt, Thomas Alistair Robertson, Deborah Ann Rathjen
  • Patent number: 6362219
    Abstract: The present invention relates to a synergistic formulation useful for the control of wide spectrum of malarial infections, which comprises a pharmaceutically effective amount of dihydroartemisinin and a vegetable oil.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: March 26, 2002
    Assignee: Council of Scientific and Industrial Research
    Inventors: Dharam Chand Jain, Rajendra Singh Bhakuni, Ram Prakash Sharma, Sushil Kumar, Guru Prakash Dutta
  • Patent number: 6306896
    Abstract: The invention relates to a pharmaceutically active composition containing a substance which is active against malaria parasites and shows a high level of activity against multiresistant lines of Plasmodium falciparum. The inventive composition is characterized in that it contains the active agent artemisinine and/or a derivative of artemisinine in a carrier material which is inert with the active agent, in a pharmaceutically active quantity and in that the carrier material is essentially free of compounds with a hydrophilic-lipophilic balance between 7 and 9.9.
    Type: Grant
    Filed: June 12, 2000
    Date of Patent: October 23, 2001
    Assignee: Mepha AG
    Inventor: Max Werner Scheiwe
  • Patent number: 6291488
    Abstract: The invention relates to combinations of atovaquone and proguanil, their use in the treatment and prophylaxis of parasitic infections such as protozoal parasitic infections, e.g., malaria and toxoplasmosis, and infections caused by P. carinii and their use in the manufacture of medicaments for the treatment and/or prophylaxis of such infections. The combinations can conveniently be administered in a single pharmaceutical formulation. Preferably, atovaquone and proguanil are administered in a potentiating ratio so that they act in synergy.
    Type: Grant
    Filed: October 4, 2000
    Date of Patent: September 18, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Winston Edward Gutteridge, David Brian Ashton Hutchinson, Victoria Susan Latter, Mary Pudney
  • Patent number: 6284772
    Abstract: Compounds, compositions and methods are provided for treating malaria parasites in vitro and in vivo by administering indolo[2,1-b]quinazoline-6,12-dione compounds of Formula I.
    Type: Grant
    Filed: September 28, 1999
    Date of Patent: September 4, 2001
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Kevin K. Pitzer, John P. Scovill, Dennis E. Kyle, Lucia Gerena
  • Patent number: 6242428
    Abstract: The invention relates to novel nucleosides and nucleoside dimers containing an L-sugar in at least one of the nucleosides, and their pharmaceutical compositions.
    Type: Grant
    Filed: December 23, 1998
    Date of Patent: June 5, 2001
    Assignees: Unisearch Limited, Lipitek International Inc.
    Inventors: Alexander L Weis, Kirupathevy Pulenthiran, Annette M. Gero
  • Patent number: 6214864
    Abstract: The present invention relates to a synergistic formulation useful for the control of wide spectrum of malarial infections, which comprises a pharmaceutically effective amount of dihydroartemisinin and a vegetable oil.
    Type: Grant
    Filed: March 5, 1999
    Date of Patent: April 10, 2001
    Assignee: Council of Scientific and Industrial Research
    Inventors: Dharam Chand Jain, Rajendra Singh Bhakuni, Ram Prakash Sharma, Sushil Kumar, Guru Prakash Dutta
  • Patent number: 6214350
    Abstract: This invention relates to compositions derived from Chinese herbal medicines, medicinal plants and extracts thereof, and to their use for the treatment of animals infected with viruses, especially with hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). More specifically, the compositions of the present invention arc derived from various Chinese herbal medicines or medicinal plants which have a long history of human consumption. The compositions of the invention are obtained through specific techniques and have demonstrated outstanding efficacy for treating human HBV carriers and hepatitis C patients. Compositions according to the invention have also exhibited in vitro antiviral activities against murine leukemia virus (MuLV) and HIV. HIV is the virus known to cause acquired immunodeficiency syndrome (AIDS) in humans and AIDS presents special problems to the medical community which the present invention addresses.
    Type: Grant
    Filed: August 17, 1999
    Date of Patent: April 10, 2001
    Inventor: Shie-Ming Hwang
  • Patent number: 6194401
    Abstract: A description is given of new pharmaceutical compositions containing cyclosporine, combined with a carrier comprising at least a derivative of &agr;-glycerophosphoric acid, such as &agr;-glycerophosphorylcholine, &agr;-glycerophosphorylserine, &agr;-glycerophosphorylethanolamine and &agr;-glycerophosphoryl-myo-inositol, which allow cyclosporine bioavailability to significantly increase.
    Type: Grant
    Filed: November 18, 1998
    Date of Patent: February 27, 2001
    Assignee: Flarer S.A.
    Inventor: Alberto Salini
  • Patent number: 6191270
    Abstract: Nucleic acids (SEQ ID NOs: 1-3) encoding a Plasmodium falciparum liver stage antigen, the LSA-3 immunogenic polypeptide, recombinant vectors containing the nucleic acids, and methods of making the polypeptide using the nucleic acids and vectors are disclosed.
    Type: Grant
    Filed: February 6, 1998
    Date of Patent: February 20, 2001
    Assignee: Institut Pasteur
    Inventors: Pierre Druilhe, Pierre Daubersies
  • Patent number: 6166046
    Abstract: The invention relates to combinations of atovaquone and proguanil, their use in the treatment and prophylaxis of parasitic infections such as protozoal parasitic infections, e.g., malaria and toxoplasmosis, and infections caused by P. carinii and their use in the manufacture of medicaments for the treatment and/or prophylaxis of such infections. The combinations can conveniently be administered in a single pharmaceutical formulation. Preferably, atovaquone and proguanil are administered in a potentiating ratio so that they act in synergy.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: December 26, 2000
    Assignee: Glaxo Wellcome Inc.
    Inventors: Winston Edward Gutteridge, David Brian Ashton Hutchinson, Victoria Susan Latter, Mary Pudney
  • Patent number: 6114393
    Abstract: Inhibitors of the sodium-hydrogen exchanger are suitable on their own or in combination with other classes of active compound for the production of a medicament for the treament of diseases which are caused by protozoa; thus of diseases which are caused by animal- and human-pathogenic protozoa, such as by intracellularly active parasites of the classes Apicomplexa and Zoomastigophorea, in particular trypanosomes, plasmodia (malaria pathogens), leishmanias, babesias and theilerias, cryptosporidiidae, sarcocystidae, amoebae, coccidia and trichomonads.
    Type: Grant
    Filed: August 26, 1998
    Date of Patent: September 5, 2000
    Assignee: Hoechst Marion Roussel Deutschland GmbH
    Inventors: Hans Jochen Lang, Michael Lanzer, Jochen Wiesner, Cecilia Sanchez, Stefan Wunsch
  • Patent number: 6110697
    Abstract: Histone deacetylase inhibition provides a target for identifying potential antiprotozoal compounds. Histone deacetylase inhibitors are useful as therapeutic agents against protozoal infections.
    Type: Grant
    Filed: September 20, 1996
    Date of Patent: August 29, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Paula M. Dulski, Robert W. Myers, Anne M. Gumett, Sandra J. Rattray, Dennis M. Schmatz
  • Patent number: 6096788
    Abstract: The invention concerns pharmaceutical compositions with antimalaria and antibabesiosis activity, the active substances of these compositions and their use for formulating antimalaria drugs.
    Type: Grant
    Filed: February 1, 1999
    Date of Patent: August 1, 2000
    Assignee: Virbac S.A.
    Inventors: Henri Vial, Michele Calas, Marie-Laure Ancelin, Louis Giral
  • Patent number: 6068987
    Abstract: Histone deacetylase inhibition provides a target for identifying potential antiprotozoal compounds. Histone deacetylase inhibitors are useful as therapeutic agents against protozoal infections.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: May 30, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Paula M. Dulski, Robert W. Myers, Anne M. Gurnett, Sandra J. Rattray, Dennis M. Schmatz
  • Patent number: 6066623
    Abstract: A first embodiment is a specific plasmid vector, pDIP/PyCSP.1, into which nucleotides encoding the targets of specific immune responses are inserted. These targets include, but are not limited to proteins and peptides. These plasmid constructs are incorporated in a composition comprising a suitable and acceptable art recognized pharmaceutical reagent that is benign (non-reactive with) to the plasmid construct. The plasmid construct provides protective immune responses to the disease associated with the selected targets. A second embodiment is a construct having, at a minimum, the nucleotide sequences encoding one or more Plasmodium species proteins in a pharmaceutically acceptable vector. a third embodiment is a method of controlling malaria in mammals comprising injecting a polynucleotide delivery vector into a mammal.
    Type: Grant
    Filed: November 23, 1993
    Date of Patent: May 23, 2000
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventors: Stephen L. Hoffman, Richard C. Hedstrom, Martha Sedegah
  • Patent number: 6048867
    Abstract: A method of therapy wherein there is administered to a person in need of such therapy a pharmacologically effective amount of a rupununine having the formula: ##STR1##
    Type: Grant
    Filed: August 12, 1996
    Date of Patent: April 11, 2000
    Inventor: Conrad Gorinsky
  • Patent number: 6043231
    Abstract: A method for treating mammals suffering from conditions associated with excess phospholipase A.sub.2 activity and/or production comprising administering to the mammal an effective amount of a non-antimicrobial tetracycline sufficient to inhibit excess phospholipase A.sub.2 activity and/or production is disclosed. A pharmaceutical composition is also disclosed.
    Type: Grant
    Filed: August 31, 1993
    Date of Patent: March 28, 2000
    Assignee: The Research Foundation of State Univ. of New York
    Inventors: Waldemar Pruzanski, Lorne M. Golub, Peter Vadas, Robert A. Greenwald, Nangavarum S. Ramamurthy, Thomas F. McNamara
  • Patent number: 5998449
    Abstract: The invention relates to combinations of atovaquone and proguanil, their use in the treatment and propinylaxis of parasitic infections, such as protozoal parasitic infections, e.g. malaria and toxoplasmosis, and infections caused by P.carinii and their use in the manunfacture of medicaments for the treatment and/or prophylaxis of such infections. The combinations can conveniently be administered in a single pharmaceutical formulation. Preferably, atovaquone and proguanil are administered in a potentiating ratio so that they act in synergy.
    Type: Grant
    Filed: October 31, 1997
    Date of Patent: December 7, 1999
    Assignee: Glaxo Wellcome Inc.
    Inventors: Winston Edward Gutteridge, David Brian Ashton Hutchinson, Victoria Susan Latter, Mary Pudney
  • Patent number: 5998476
    Abstract: The invention provides polyunsaturated fatty acid compounds having antimalarial and/or neutrophil stimulatory activity, or anti-inflammatory activity. The polyunsaturated fatty acids contain a 16-26 carbon chain, 3-6 double bonds and are covalently coupled at the carboxylic acid group to an amino acid. It is preferred that the fatty acid contains 18-22 carbons and that the amino acid is glycine or aspartic acid. Preferred compounds are .gamma.-linolenic acid-glycine, .alpha.-linolenic acid-glycine, arachidonic acid-aspartic acid, eicosapentaenoic acid-aspartic acid and docosahexaenoic acid-aspartic acid.
    Type: Grant
    Filed: July 21, 1997
    Date of Patent: December 7, 1999
    Assignee: Peptide Technology Limited
    Inventors: Merilyn Joy Sleigh, Fred Widmer, Paul Adam Schober, Antonio Ferrante, Alfred Poulos, Deborah Ann Rathjen
  • Patent number: 5968987
    Abstract: The present invention relates to the use of halofantrine free base in the treatment of malarial infections. In particular, lipid-based formulations for oral and injectable use are disclosed.
    Type: Grant
    Filed: October 15, 1997
    Date of Patent: October 19, 1999
    Assignee: Smithkline Beecham p.l.c.
    Inventors: William Neil Charman, Christopher John Hamilton Porter
  • Patent number: 5955490
    Abstract: Methods of detecting and treating rapidly growing exogenous cells, such as Protista, or parasites, that preferentially accumulate a photoactivatable porphyrin in which 5-aminolevulinic acid or precursor thereof is administered to the patient, or contacted to the exogenous cells, in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of a protoporphyrin IX in the exogenous cells, followed by exposure of the exogenous cells to light of photoactivating wavelengths.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: September 21, 1999
    Assignee: Queen's University at Kingston
    Inventors: James C. Kennedy, Roy H. Pottier, Robert L. Reid, Arnold Sac-Morales, Lewis L. Tomalty
  • Patent number: 5939402
    Abstract: The invention relates to novel nucleosides and nucleoside dimers containing an L-sugar in at least one of the nucleosides, and their pharmaceutical compositions.
    Type: Grant
    Filed: March 11, 1998
    Date of Patent: August 17, 1999
    Assignee: Lipitek International, Inc.
    Inventors: Alexander L. Weis, Kirupathevy Pulenthiran
  • Patent number: 5928636
    Abstract: The present invention provides a combination of IL-12 and IFN.alpha. together with a pharmaceutically acceptable carrier useful for treatment and prophylaxis of infectious diseases, preferably chronic infectious diseases and more preferably viral infections, e.g. HSV, HIV, Hepatitis B, Hepatitis C, papilloma etc., bacterial infections, e.g. tuberculosis, salmonellosis, listeriosis, etc., and parasite infections, e.g. malaria, leishmaniasis, and schistosomiasis. These compositions are characterized by the synergistic interaction of IL-12 and IFN.alpha.. The present invention also provides the use of the above combination for the treatment and prophylaxis of infectious diseases.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: July 27, 1999
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Gottfried Alber, Jacqueline Anne Carr, Frank Albert Mattner, Michael John Mulqueen, Kathrin Palmer, Jane Andre Louise Rogerson
  • Patent number: 5902793
    Abstract: This invention is directed to a method for stimulating, the proliferation of V.gamma.2V.delta.2 T cells comprising contacting V.gamma.2V.delta.2 T cells with a V.gamma.2V.delta.2 T cell proliferation stimulating amount of a compound selected from the group-consisting of a monoalkyl phosphate, a hydroxy monoalkyl phosphate, a carboxy monoalkyl phosphate, a monoalkyl pyrophosphate, an alkenyl pyrophosphate, a .gamma.-monoalkyl nucleoside triphosphate, a .gamma.-monoalkyl deoxnucleoside triphosphate, a .gamma.-alkenyl nucleoside triphosphate, and a .gamma.-alkenyl deoxynucleoside triphosphate.
    Type: Grant
    Filed: June 16, 1997
    Date of Patent: May 11, 1999
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Barry R. Bloom, Yoshimasa Tanaka, Shigetoshi Sano
  • Patent number: 5885996
    Abstract: Quinazoline compounds which demonstrate antiproliferative activity, such as antitumor activity, processes of preparing these compounds, pharmaceutical compositions containing these compounds, and the use of these compounds. These compounds inhibit the growth and proliferation of the cells of higher organisms and microorganisms, such as bacteria, yeasts and fungi. Preferred quinazoline compounds are capable of inhibiting the enzyme thymidylate synthase. Effects derived from the inhibition of the enzyme thymidylate synthase include those discussed above.
    Type: Grant
    Filed: September 4, 1997
    Date of Patent: March 23, 1999
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Stephen E. Webber, Ted M. Bleckman, John Attard, Terrence R. Jones, Michael D. Varney
  • Patent number: 5883132
    Abstract: The present invention relates to compounds selected from the group consisting of:(i) the compounds of the formula ##STR1## in which: R is a hydrogen atom, a group OH, a group OCH.sub.3 or a group CH.sub.2 OH,*C, in the case where R is not a hydrogen atom, is an asymmetric carbon atom of (R,S), (R) or (S) configuration, and**C is an asymmetric carbon atom of (R,S) or (R) configuration; and(ii) their addition salts.It further relates to the method of preparing these compounds, to their use in therapeutics and in the field of analysis, and to intermediates.
    Type: Grant
    Filed: October 10, 1996
    Date of Patent: March 16, 1999
    Assignee: Fournier Industrie Et Sante
    Inventors: Luc Lebreton, Patrice Renaut, Philippe Durand
  • Patent number: 5874477
    Abstract: The invention provides a method of preventing or treating malaria comprising administering a therapeutically effective amount of serotonin receptor ligand to reduce the pathological consequences of malaria infection in a patient, said serotonin receptor ligand characterized by an ability to displace an identifying ligand which defines the serotonin receptor subtype 5HT1a or 5HT2/5HT1c.In addition, the invention provides a method of identifying a serotonin receptor ligand capable of reducing the pathological consequences of malarial infection in a patient comprising the step of sequentially assaying potential ligands to identify a ligand characterized by an ability to displace an identifying ligand which defines the serotonin receptor subtype 5HT1a or 5HT2/5HT1c.
    Type: Grant
    Filed: August 12, 1994
    Date of Patent: February 23, 1999
    Assignee: The University of Hawaii
    Inventors: Bruce McConnell, Christopher P. Locher
  • Patent number: 5798106
    Abstract: This invention relates to a novel protein capable of inducing an immune response protective against human malarial infection caused by Plasmodium falciparum, and to the cloning and expression of a gene encoding the said protein. The invention further relates to novel vaccines comprising the said protein and to their use in the vaccination of humans at risk from malaria.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: August 25, 1998
    Assignee: University of Nijmegan
    Inventors: Johannes Gerardus Ghislain Schoenmakers, Rudolph Nicholaas Hendrik Konings, Inge Irma Maria Dominique Moelans
  • Patent number: 5753632
    Abstract: The use of colloidal silica for the treatment of sickle-cell anaemia, malaria and exogenously induced leucopenias leads to a significant improvement in the condition of the patients.
    Type: Grant
    Filed: September 21, 1995
    Date of Patent: May 19, 1998
    Inventors: Alfred Schmidt, Emmanuel Bisse, Heinrich Wieland
  • Patent number: 5711966
    Abstract: This invention provides a method of treating patients suffering from malaria whilst avoiding cardioarrhythmias, the improvement thereof comprising the administration of desbutylhalofantrine in place of halofantrine. Dosage of 500 mg every six hours for three doses on day one with repeat of that dosage on day 7 for a total dosage of 3000 mg is appropriate for most treatment purposes in adults. Desbutylhalofantrine may also be given at dosage of 50 to 1000 mg as a prophylactic measure. Dosage may be given daily or one day per week.
    Type: Grant
    Filed: August 23, 1996
    Date of Patent: January 27, 1998
    Inventors: Raymond Woosley, David L. Wesche, Brian G. Schuster
  • Patent number: 5683692
    Abstract: A method of treating viral and protozoal infections using RIPonucleases is provided.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 4, 1997
    Assignee: Thomas Jefferson University
    Inventors: Theodore Taraschi, Emmanuelle Nicolas
  • Patent number: 5677331
    Abstract: The invention relates to a synergistic antimalarial composition which comprises the antimalarial agent benflumetol and also an antimalarial agent from the artemisinine group such as artemether. The composition can be formulated into solid dosage forms such as tablets and is useful for the treatment of drug resistant malaria.
    Type: Grant
    Filed: March 23, 1994
    Date of Patent: October 14, 1997
    Assignees: Ciba-Geigy AG, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences
    Inventors: Yiqing Zhou, Dianxi Ning, Shufen Wang, Deben Ding, Guofu Li, Chengqi Shan, Guangyu Liu
  • Patent number: 5672624
    Abstract: The present invention relates to novel biologically-active organic peroxides and to novel uses of both known and new organic peroxides. More specifically, this invention details organic endoperoxides having antiparasitic activity, methods for their preparation and methods for treating malaria and cerebral toxoplasmic encephalitis with the organic endoperoxides.
    Type: Grant
    Filed: November 22, 1995
    Date of Patent: September 30, 1997
    Assignee: The Johns Hopkins University
    Inventor: Gary H. Posner
  • Patent number: 5658949
    Abstract: A novel method of inhibiting production of two important mediators of cellular function, tumor necrosis factor and nitric oxide, and treating a pathophysiological state characterized by an undesirable production or level of tumor necrosis factor or nitric acid. The methods of the present invention employ retinoic acid compounds. The most preferred retinoic acid is all-trans-retinoic acid. Also provided is a method of inhibiting tumor necrosis factor receptors using retinoic acid-like compounds.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: August 19, 1997
    Assignee: Research Development Foundation
    Inventor: Bharat B. Aggarwal
  • Patent number: 5624913
    Abstract: A method for reducing the TNF-alpha in mammals with cerebral malaria comprising the administration of 2-methylthio-ATP or 2-chloro-ATP.
    Type: Grant
    Filed: August 30, 1994
    Date of Patent: April 29, 1997
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Richard A. Proctor, Paul J. Bertics
  • Patent number: 5569456
    Abstract: A rupununine, either in purified form or a derivative in which one or both of the hydroxyl groups is substituted, the rupununine having the formula: ##STR1## where R.dbd.--H or --CH.sub.3.
    Type: Grant
    Filed: February 1, 1994
    Date of Patent: October 29, 1996
    Inventor: Conrad Gorinsky
  • Patent number: 5569675
    Abstract: This invention relates to novel methods of increasing the level of fetal hemoglobin (HbF) in a subject and methods of treating, preventing or ameliorating .beta.-globin or other HbF-related disorders by increasing the level of HbF in a subject in need of such treatment comprising administering one or more compounds of the Formulae (I), (II), or (III):(I) XCH.sub.2 --CHX--CHX--C(.dbd.O)--O--Z(II) CH.sub.3 --CO--CH.sub.2 --C(.dbd.O)--O--Z(III) CH.sub.3 --CH.sub.2 --CO--C(.dbd.O)--O--Zwherein:X is H, or one of X only may be OH;Z is --CHR--O--C(.dbd.O)R', --CHR--O--C(.dbd.
    Type: Grant
    Filed: March 7, 1994
    Date of Patent: October 29, 1996
    Assignees: Bar Ilan University, Mor Research Applications Ltd.
    Inventors: Ada Rephaeli, Abraham Nudelman, Matityahu Shaklai
  • Patent number: 5516806
    Abstract: Compounds of formula (I): H.sub.2 N--(CH.sub.2).sub.n --A--(CH.sub.2).sub.m --O--NH.sub.2 and salts thereof are described in which the radical A is C.sub.3 -C.sub.6 cycloalkylene; n is 0 or 1 and, independently thereof, m is 0 or 1; with the provisos that a) the distance between the aminooxy radical H.sub.2 N--O-- and the amino group --NH.sub.2 is at least 3 and not more than 4 carbon atoms and that b) the two radicals H.sub.2 N--(CH.sub.2).sub.n -- and --(CH.sub.2).sub.m --O--NH.sub.2 are not bonded to the same ring carbon of A. The compounds of formula (I) and their salts are ornithine decarboxylase inhibitors.
    Type: Grant
    Filed: December 12, 1994
    Date of Patent: May 14, 1996
    Assignee: Ciba-Geigy Corporation
    Inventors: Jorg Frei, Jaroslav Stanek